13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001910264
Total reported value
$1.0B
$1.0B
13 檔
54.0%
As reported in its official Q4 2025 Form 13F filing, Sr One Capital Management, LP's tracked investment portfolio stood at $1.0B with 13 total positions.
In Q4 2025, Sr One Capital Management, LP displayed an active expansion posture, initiating 1 new positions and adding to 2 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZBIO | Zenas Biopharma Inc | Stock-Other | 25.90% | +1.55% | +2.57% | |
| 2 | ACLXGBX | Arcellx Inc | Stock-Other | 21.66% | -29.43% | EXIT | |
| 3 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 15.14% | +0.11% | — | |
| 4 | DSGN | Design Therapeutics Inc | Stock-Other | 8.67% | +1.50% | — | |
| 5 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 8.03% | -0.57% | -26.02% | |
| 6 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 6.62% | -0.43% | — | |
| 7 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 5.34% | -1.58% | — | |
| 8 | ALMS | Alumis Inc | Stock-Other | 2.71% | +0.59% | — | |
| 9 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.85% | -2.31% | EXIT | |
| 10 | OCS | Oculis Holding AG | Stock-Other | 1.81% | -1.00% | +98.77% | |
| 11 | ✓ | Engene Holdings Inc | Stock-Other | 0.96% | -0.44% | — | |
| 12 | NKTX | Nkarta Inc | Stock-Other | 0.87% | +0.14% | — | |
| 13 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.45% | +0.12% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ZBIO | Zenas Biopharma Inc | +10.1% | +2.57% | Add |
| 2 | ALMS | Alumis Inc | +1.6% | — | Unchanged |
| 3 | DSGN | Design Therapeutics Inc | +1.6% | — | Unchanged |
| 4 | OCS | Oculis Holding AG | +1% | +98.77% | Add |
| 5 | SPRY | Ars Pharmaceuticals Inc | +0.8% | — | Unchanged |
| 6 | ORKA | Oruka Therapeutics Inc | +0.7% | — | Unchanged |
| 7 | ✓ | Engene Holdings Inc | +0.2% | — | Unchanged |
| 8 | NKTX | Nkarta Inc | -0.1% | — | Unchanged |
| 9 | ORIC | Oric Pharmaceuticals Inc | -2.5% | — | Unchanged |
| 10 | MLYS | Mineralys Therapeutics Inc | -3.6% | -26.02% | Trim |
| 11 | CRSP | CRISPR Therapeutics AG | -4% | — | Unchanged |
| 12 | ACLXGBX | Arcellx Inc | -6.2% | — | Unchanged |
| 13 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
According to official SEC Form 13F filings, Sr One Capital Management, LP reported a total U.S. public equity portfolio value of $1.0B across 13 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ZBIO, ACLXGBX, CRSP) accounted for 54.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
RARE
市值: $3.2M
Top Position Liquidated / Trimmed
MLYS
前期市值: $80.2M
During Q4 2025, Sr One Capital Management, LP's top holdings by market value included ZBIO (25.9%)、ACLXGBX (21.7%)、CRSP (15.1%). The largest single position, ZBIO, represented 25.9% of total portfolio value.
In Q4 2025, Sr One Capital Management, LP made 4 total portfolio adjustments, initiating 1 new buys, adding to 2 positions, trimming 1 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.